Roche solid in 2013 but modest dividend raises questions
This article was originally published in Scrip
Executive Summary
True to expectation, Roche has reported a solid performance for the full year, and as the first of the European big pharma companies, it has likely set a trend for reporting negative currency effects among its peers (scripintelligence.com, 28 January 2014).